Literature DB >> 9458012

Conversion of pancreas allograft rejection to acceptance by liver transplantation.

C Wang1, J Sun, L Li, L Wang, P Dolan, A G Sheil.   

Abstract

BACKGROUND: Liver allografts of PVG(RT1c)-->DA(RT1a) are spontaneously accepted, whereas pancreas, heart, and kidney allografts are rejected. Our previous studies have shown that simultaneous liver and pancreas transplantation prevents pancreas allograft rejection. The aim of this study was to examine the effect of liver transplantation on subsequent pancreas allografts and on ongoing pancreas rejection.
METHODS: Heterotopic, duct-ligated segmental pancreas grafts were transplanted into streptozotocin-induced diabetic recipients (60 mg/kg body weight i.p.) with or without orthotopic liver grafting at different times. Experimental design was as follows. Group 1 received PVG-->PVG pancreas syngrafts (n=6); group 2, PVG-->DA pancreas allografts (n=7); groups 3-5, PVG-->DA pancreas allografts followed by liver transplantation on day 2 (n=6), on day 4 (n=5), and on day 6 (n=5), respectively, group 6, PVG-->DA pancreas allografts after liver transplantation at 4 weeks (n=6).
RESULTS: The results showed that pancreas allografts in group 2 were rejected from postoperative day 7 to 13. Liver transplantation prevented subsequent pancreas allograft rejection in group 6. Ongoing pancreas rejection was reversed by liver transplantation with subsequent graft acceptance in groups 3-5. Significant graft-infiltrating lymphocyte apoptosis was demonstrated at 2 weeks in pancreas transplants associated with liver grafting. Graft-versus-host disease was not detected in the pancreas recipients.
CONCLUSIONS: We conclude that pancreas allografts in the PVG-->DA combination are rejected rapidly with median survival time of 9 days. Liver transplantation can protect subsequent pancreas grafts from rejection and reverse ongoing pancreas graft rejection with subsequent pancreatic acceptance. Graft-infiltrating lymphocyte apoptosis may be associated with the process of graft acceptance.

Entities:  

Mesh:

Year:  1998        PMID: 9458012     DOI: 10.1097/00007890-199801270-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

Review 1.  Tolerance and chimerism and allogeneic bone marrow/stem cell transplantation in liver transplantation.

Authors:  Sheng-Li Wu; Cheng-En Pan
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

2.  In the Acute Phase of Trypanosoma cruzi Infection, Liver Lymphoid and Myeloid Cells Display an Ambiguous Phenotype Combining Pro- and Anti-Inflammatory Markers.

Authors:  Carina de Lima Pereira Dos Santos; Natalia Vacani-Martins; Cynthia Machado Cascabulho; Mirian Claudia de Souza Pereira; Ian Nicholas Crispe; Andrea Henriques-Pons
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

3.  Unique CD8+ T Cell-Mediated Immune Responses Primed in the Liver.

Authors:  Jason M Zimmerer; Phillip H Horne; Mason G Fisher; Thomas A Pham; Keri E Lunsford; Bryce A Ringwald; Christina L Avila; Ginny L Bumgardner
Journal:  Transplantation       Date:  2016-09       Impact factor: 4.939

Review 4.  Liver transplant tolerance and its application to the clinic: can we exploit the high dose effect?

Authors:  Eithne C Cunningham; Alexandra F Sharland; G Alex Bishop
Journal:  Clin Dev Immunol       Date:  2013-11-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.